AZACITIDINE MYLAN 25 mg/ml, powder for injectable suspension bottle
Active ingredients: Azacitidine
Commercialized according to BDPMDispensing in France: Prescription only
Powder for injectable suspensionbottlesous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- AZACITIDINE MYLAN 25 mg/mL, poudre pour suspension injectable
- Pharmaceutical form
- poudre pour suspension injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 100 mg
- Marketing authorisation holder
- MYLAN PHARMACEUTICALS (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 14 Sept 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66041282CIP73020499CIP133400930204993Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| AZACITIDINEpoudre | 25 mg · 1 mL de suspension reconstituée | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.